Clinical Trial News and Research

RSS

Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract.

8 Sep 2009

$geneX combined with Mesenchymal stem cells for treating fracture$

geneX combined with Mesenchymal stem cells for treating fracture

Professor James B. Richardson of the Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK has been carrying out pioneering work combining geneX with selected and culture expanded Mesenchymal stem cells to treat fracture non-unions.

7 Sep 2009

Identifying a specific molecular signature can help customize cancer treatment

A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant to therapies, will be published September 6 in the advance online edition of Nature Medicine.

7 Sep 2009

The Jordanian Stem Cell Company signs purchase agreement with Stemedica International

Stemedica Cell Technologies, Inc., ("Stemedica"), a world leader in stem cell research and manufacturing, announced the signing of an agreement today for its breakthrough stem cell and related technology. The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement to purchase the technology from Stemedica's wholly-owned subsidiary, Stemedica International, S.A.

7 Sep 2009

Taskforce formed to help speed licensure, vaccine distribution following RTS,S trials

GNA/Peace FM examines the recent creation of a local and international taskforce to help shorten the window of time between the completion of the clinical trial of the RTS,S malaria vaccine - currently being tested across Africa - and licensure and vaccine distribution. According to the news service, scientists recently launched a Phase III trial of the RTS,S vaccine in Kintampo, Ghana, which will include 1,200 children, between the ages of 6-12 weeks and 5-17 months.

5 Sep 2009

Sinovac to purchase H1N1 vaccine for the national stockpiling plan

Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Ministry of Industry and Information Technology of the People's Republic of China has issued the initial order to Sinovac to purchase H1N1 vaccine for the national stockpiling plan.

5 Sep 2009

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Hard to Treat Diseases (the "Company") announced today, that its China based subsidiary Mellow Hope, has just finished (August 2009) the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India.

5 Sep 2009

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Human Genome Sciences, Inc. today announced publication by the journal Arthritis Care & Research of an article describing the development and use of a novel evidence-based systemic lupus erythematosus (SLE) Responder Index selected as the primary endpoint of two pivotal Phase 3 clinical trials of BENLYSTA (belimumab) in serologically active patients with SLE.

4 Sep 2009

Dilafor Phase II clinical trial completes

Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth.

4 Sep 2009

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company’s potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

4 Sep 2009

Phase III clinical trial results of XIAFLEX published in a journal

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products today announced results of the pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of Dupuytren's disease, was published in today's edition of the New England Journal of Medicine.

4 Sep 2009

nSpire Health awarded over $9 million for clinical research trials

nSpire Health, a leading global manufacturer of respiratory diagnostic products and services, announced today clinical trial research services awards of over $9 million in August. The trials awarded by prominent pharmaceutical companies include the company’s eSP™ core lab services, gold standard KoKo® spirometry, and new patent pending PiKoLogic® electronic patient reported outcomes (ePRO) solution.

4 Sep 2009

Helix Biopharma raises funds through private placement

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at $2.05 per unit, for gross proceeds totaling CDN$13,581,250.

4 Sep 2009

Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response

Results from the first swine-flu vaccine trials taking place in Leicester reveal a strong immune response after just one dose.

4 Sep 2009

ERT celebrates a significant milestone: Completes 150Th QT clinical Trial

ERT (Nasdaq: ERES) has celebrated a significant milestone by completing its 150th thorough QT clinical Trial (TET). ERT provides full TET support to the biopharmaceutical industry, including consultation, study design, and provision of ECG equipment to ECG analysis, data processing, management, reconciliation, reporting, quality control and regulatory support.

4 Sep 2009

IND for Cytopia's CYT387 clears the FDA review

Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.

4 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

NCI renews SPORE grant for the diagnosis and treatment of ovarian cancer

National Cancer Institute (NCI) has renewed a $11.5 million Specialized Program of Research Excellence (SPORE) grant in prevention, diagnosis and treatment of ovarian cancer, which supports multidisciplinary research at Fox Chase Cancer Center and the University of Pennsylvania. First approved in 1999, this marks the third five-year term for the Fox Chase-Penn Ovarian SPORE.

4 Sep 2009

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

3 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

Clinical Trial News and Research

Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION

geneX combined with Mesenchymal stem cells for treating fracture

Identifying a specific molecular signature can help customize cancer treatment

The Jordanian Stem Cell Company signs purchase agreement with Stemedica International

Taskforce formed to help speed licensure, vaccine distribution following RTS,S trials

Sinovac to purchase H1N1 vaccine for the national stockpiling plan

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Novel SLE Responder Index as the primary endpoint in two Phase 3 clinical trials

Dilafor Phase II clinical trial completes

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

Phase III clinical trial results of XIAFLEX published in a journal

nSpire Health awarded over $9 million for clinical research trials

Helix Biopharma raises funds through private placement

Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response

ERT celebrates a significant milestone: Completes 150Th QT clinical Trial

IND for Cytopia's CYT387 clears the FDA review

Results of Phase 2 rheumatoid arthritis clinical trial announced

NCI renews SPORE grant for the diagnosis and treatment of ovarian cancer

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News